TELA Bio received U.S. clearance for its Liora Monofilament Scaffold, removing a regulatory barrier to offering it. The filing gives no sales or customer-demand results, so commercial success is not yet shown.
This gives TELA a step toward offering the product in the United States. The filing reports clearance, but no sales or customer-demand results. The benefit depends on whether hospitals choose to use it.
Follow TELA Bio, Inc. (TELA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TELA